CRMD News and Press, CorMedix Inc. From 05/11/22

AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...

BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its...

BERKELEY HEIGHTS, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the formation of a new...

BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that management will b...

CorMedix (CRMD +12.8%) stock rose following its Q4 results, which beat analysts' estimates. Q4 net revenue remained largely flat at $56.4K, compared to $55.7K in Q4 2020. Net loss widened to -$7.8M, compared to a net loss of -$6.1M in Q4 2020. The company said the increase in net loss wa...

CorMedix Inc. (CRMD) Q4 2021 Earnings Conference Call March 29, 2022 04:30 PM ET Company Participants Daniel Ferry - LifeSci Advisors, Investor Relations Matt David - Interim Chief Executive Officer, Executive Vice President and Chief Financial Officer Phoebe Mounts - Executive Vice President...

Image source: The Motley Fool. CorMedix Inc Common Stock (NASDAQ: CRMD) Q4 2021 Earnings Call Mar 29, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: CorMedix Inc Common Stock (CRMD) Q4 2021 Earnings Call Transcript...

CorMedix press release (NASDAQ:CRMD): Q4 GAAP EPS of -$0.20 beats by $0.03. Revenue of $0.06M (flat Y/Y) beats by $0.05M. For further details see: CorMedix GAAP EPS of -$0.20 beats by $0.03, revenue of $0.06M beats by $0.05M

BERKELEY HEIGHTS, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for ...

CorMedix (NASDAQ:CRMD) is scheduled to announce Q4 earnings results on Tuesday, March 29th, after market close. The consensus EPS Estimate is -$0.23 (-21.1% Y/Y) and the consensus Revenue Estimate is $0.01M (-83.3% Y/Y). For further details see: CorMedix Q4 2021 Earnings Preview